The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: A retrospective cohort study

Modern Rheumatology

Volumn 18, Issue 6, 2008, Pages 609-614

  Suda, Akiko ^a,b   Nagaoka, Shouhei ^a   Ohono, Shigeru ^b   Ideguchi, Haruko ^b   Soga, Takayoshi ^b   Ishigatsubo, Yoshiaki ^a  

^a Yokohama Minami Kyosai Hospital   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bucillamine; DMARD; MTX; Rheumatoid arthritis; Sulfasalazine; Switching therapy

Indexed keywords

BUCILLAMINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CHEILITIS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RASH; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; STOMATITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; CYSTEINE; FEMALE; HEALTH STATUS; HUMANS; JOINTS; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 57649238780     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-008-0103-7     Document Type: Article

References (20)

1. Abe C. Clinical evaluation of immunomodulators. Int J Immunother. 1985;1:7-10.
2. Kashiwazaki S, Shiokawa Y. Bucillamine: A new immunomodulator. Int J Immunother. 1987;3:1-6.
3. Nagashima M, Shu G, Yamamoto K, Yamahatsu S, Yoshino S. The ability of disease modifying antirheumatic drugs to induce and maintain improvement in patients with rheumatoid arthritis. Epidemiology of DMARDs treatment in Japan. Clin Exp Rheumatol. 2005;23(1):27-35.
4. Iwatani M, Inoue E, Nakamura T, Nakajima A, Hara M, Tomatsu T, et al. Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. Mod Rheumatol. 2006;16(6):376-80.
5. Mimori T. Anti-rheumatic drugs. In: Ochi T, Yamamoto K, Ryuu J, editors. Manual of diagnosis and guideline for treatment of RA. Tokyo: Japanese rheumatism foundation; 2004. pp. 84-98. (in Japanese).
6. Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: A multicenter, double-blind, randomized controlled study. Mod Rheumatol. 2005;15:323-8.
7. Hirohata S, Lipsky PE. Regulation of B cell function by bucillamine, a novel disease-modifying antirheumatic drug. Clin Immunol Immunopathol. 1993;66(1):43-51.
8. Tsuji F, Seki I, Aono H, Odani N, Mizutani K, Okamoto M, et al. Bucillamine mechanism inhibiting IL-1beta-induced VEGF production from fibroblast-like synoviocytes. Int Immunopharmacol. 2007;7(12):1569-76.
9. Suematsu A, Tajiri Y, Nakashima T, Taka J, Ochi S, Oda H, et al. Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis. Mod Rheumatol. 2007;17(1):17-23.
10. Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest. 1998;101:295-300.
11. Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996;156:1937-41.
12. Haagsma CJ, Russel FG, Vree TB, Van Riel PL, Van de Putte LB. Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: Pharmacokinetic analysis and relationship to clinical response. Br J Clin Pharmacol. 1996;42(2):195-200.
13. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination therapy in early rheumatoid arthritis: A randomized, controlled, double-blind 52-week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999;58(4):220-5.
14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
15. van Riel PLCM, van Gestel AM. Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis. 2000;59(suppl 1):i28-31.
16. Yokota N, Kuga Y, Kanazawa T, Morishita M, Tanida K, Itou K. Ten years results of bucillamine in the treatment of rheumatoid arthritis. Mod Rheumatol. 2007;17(1):33-6.
17. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381-90.
18. Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: A systematic retrospective study of 709 patients. Rheumatology (Oxford). 2007;46(2):327-34.
19. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007;56(4):1125-33.
20. Sekiguchi N, Kameda H, Amano K, Takeuchi T. Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis. Mod Rheumatol. 2006;16(2):85-91.